| http://www.w3.org/ns/prov#value | - The stock price is on pace to almost double its initial listing price on the NYSE. American Pharmaceutical Partners has also been on a roll ever since new CEO Al Heller took charge and its new cancer drug Abraxane was approved by the FDA and has launched.A number of companies continued to suffer during the year including Abbott and Eli Lilly.
|
